ArriVent BioPharma, Inc. Common Stock (AVBP) Research

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments addressing critical gaps in cancer patient care. The company specifically focuses on developing and commercializing targeted oncology therapies for conditions like non-small-cell lung cancer (NSCLC) and various solid tumor indications. Among its pipeline candidates are Furmonertinib, an epidermal growth factor receptor (EGFR) mutant-selective tyrosine kinase inhibitor currently undergoing a Phase 3 clinical trial for NSCLC treatment, and ARR-002. ArriVent maintains strategic alliances, including one with Aarvik Therapeutics Inc. Established in 2021, its operations are headquartered in Newtown Square, Pennsylvania.

Market snapshot

Symbol
AVBP
Price
$31.74
Day change
+1.21%
Market cap
$1.5B
P/E ratio
-9.85x
52-week range
16.1-33.616
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$45.00

Peer companies

  • Arvinas, Inc. (ARVN)
  • Astria Therapeutics, Inc. (ATXS)
  • Day One Biopharmaceuticals, Inc. (DAWN)
  • Ginkgo Bioworks Holdings, Inc. (DNA)
  • Erasca, Inc. (ERAS)
  • Iovance Biotherapeutics, Inc. (IOVA)
  • MBX Biosciences, Inc. Common Stock (MBX)
  • MeiraGTx Holdings plc (MGTX)

Recent insider activity

  • LaChapelle Robin — A-Award (130000 shares) on 2026-02-02
  • Lutzker Stuart — A-Award (150000 shares) on 2026-02-02
  • Kung Winston — A-Award (140000 shares) on 2026-02-02
  • Yao Zhengbin — A-Award (550000 shares) on 2026-02-02
  • Kastenmayer James Paul — A-Award (130000 shares) on 2026-02-02

Open ArriVent BioPharma, Inc. Common Stock (AVBP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.